TLSI
TriSalus Life Sciences Inc.
NASDAQ: TLSI · HEALTHCARE · MEDICAL DEVICES
$4.39
+1.62% today
Updated 2026-05-01
Market cap
$275.75M
P/E ratio
—
P/S ratio
6.11x
EPS (TTM)
$-1.84
Dividend yield
—
52W range
$3 – $8
Volume
0.2M
TriSalus Life Sciences Inc. (TLSI) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $8.40M | $12.40M | $18.51M | $29.43M | $45.15M |
| Revenue growth (YoY) | — | +47.6% | +49.3% | +59.0% | +53.4% |
| Cost of revenue | $1.19M | $2.26M | $2.60M | $4.10M | $6.96M |
| Gross profit | $7.21M | $10.14M | $15.91M | $25.33M | $38.19M |
| Gross margin | 85.8% | 81.8% | 85.9% | 86.1% | 84.6% |
| R&D | $14.22M | $21.36M | $29.84M | $17.69M | $14.96M |
| SG&A | $8.75M | $12.48M | $23.51M | $17.97M | $21.46M |
| Operating income | $-24.03M | $-36.44M | $-54.48M | $-36.16M | $-26.95M |
| Operating margin | -286.1% | -293.9% | -294.3% | -122.9% | -59.7% |
| EBITDA | $-23.57M | $-46.76M | $-58.65M | $-36.16M | $-26.95M |
| EBITDA margin | -280.5% | -377.2% | -316.9% | -122.9% | -59.7% |
| EBIT | $-24.03M | $-47.18M | $-59.34M | $-33.13M | — |
| Interest expense | $1.76M | $1000.00 | $16000.00 | $3.09M | $5.54M |
| Income tax | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-28.84M | $-47.19M | $-59.36M | $-33.23M | $-39.23M |
| Net income growth (YoY) | — | -63.6% | -25.8% | +44.0% | -18.0% |
| Profit margin | -343.4% | -380.6% | -320.7% | -112.9% | -86.9% |